GAITHERSBURG, Md., Feb. 7 /PRNewswire/ -- MedImmune today announced that it has strengthened its leadership in research, human resources (HR) and regulatory affairs with three key promotions and has also hired a new head of vaccine manufacturing. Peter A. Kiener, D. Phil. has been appointed to executive vice president, research; Katy Strei to vice president, people and organization development, HR; and Eileen Valenta to vice president, operations and compliance, regulatory affairs. In addition, Shou-Bai Chao, Ph.D. has recently joined the company as vice president of vaccine manufacturing.
"As MedImmune prepares for the next phase of its corporate growth -- including dramatic acceleration within its product portfolio, it is imperative that we have strong leadership at the helm of all aspects of our business, but particularly within the research, HR and regulatory affairs functions," said David M. Mott, chief executive officer and president.
"Peter is now driving forward our global research efforts, which span from our core antibody research center in Maryland's biotech corridor to our discovery and development center in Cambridge, UK to our vaccine research facilities in the San Francisco Bay area of California. Katy is ensuring that we have the right people -- with the right skills -- at the right time, which is critical for us to deliver on the promise of our pipeline. Eileen's contributions will grow significantly with our maturing product portfolio and its need for regulatory affairs and compliance oversight. And, as we carry forward the potential next-generation of innovative vaccines, Shou-Bai is a welcome addition to the organization," Mott added.
Dr. Peter Kiener has been promoted from senior vice president, research
to executive vice president, research, overseeing all global research
activities for the company. Since joining MedImmune in 2001, Dr. Kiener has
made expert and strategic contributions in
Copyright©2008 PR Newswire.
All rights reserved